Skip to main content

Advertisement

Table 1 Baseline characteristics of patients in two groups

From: The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma

  NT-RFA C-RFA P value
n 46 84  
Age, years 52.0 (43.0–58.0) 51.0 (45.0–59.0) 0.826
Gender, female 4 (8.7%) 6 (7.2%) 0.742*
BMI, kg/m2 23.9 (21.9–26.4) 23.6 (21.3–25.8) 0.622
Etiology    0.212*
 HBV 44 (95.7%) 74 (88.1%)  
 Others 2 (4.3%) 10 (11.9%)  
Cirrhotic basis    0.124
 Compensated 32 (69.6%) 69 (82.1%)  
 Uncompensated 14 (30.4%) 15 (17.9%)  
SLV, cm3 1405.0 (1341.0–1484.0) 1393.0 (1338.0–1454.0) 0.341
Child-Pugh    0.326*
 A 44 (95.7%) 75 (89.3%)  
 B 2 (4.3%) 9 (10.7%)  
Decompensated complications    0.102
 Bleeding varices 5 (10.9%) 2 (2.4%)  
 Hepato-renal syndrome 1 (2.2%) 0 (0)  
 Hepatic encephalopathy 2 (4.3%) 1 (1.2%)  
 Ascites 6 (13.0%) 12 (14.3%)  
Tumor size, mm 19.0 (15.0–22.0) 21.0 (16.0–26.0) 0.048
Near major vessels 12 (26.1%) 27 (32.1%) 0.551
Lab tests
 ALT, IU/l 30.5 (21.1–47.5) 31.6 (23.6–47.5) 0.450
  TBIL, μmol/L 18.8 (14.6–23.2) 16.9 (13.9–23.1) 0.301
 ALP, IU/L 107.0 (82.8–124.5) 90.0 (77.0–112.0) 0.075
  TBA, μmol/L 5.7 (2.3–13.2) 7.6 (2.9–16.2) 0.270
  PT, sec 11.9 (11.4–12.5) 12.0 (11.3–12.9) 0.327
  Alb, g/L 44.7 (39.8–46.7) 44.8 (40.1–47.4) 0.634
  PLT, 10^9/L 116.0 (88.0–163.3) 118.5 (78.5–147.5) 0.376
 AFP, ng/ml 27.3 (4.4–224.6) 13.0 (3.3–105.8) 0.102
  1. *Fisher’s exact test
  2. RFA radio frequency ablation, BMI body mass index, HBV hepatitis B virus, SLV standard liver volume, ALT alanine aminotransferase, TBIL total bilirubin, ALP alkaline phosphatase, TBA total bile acid, PT prothrombin time, Alb albumin, PLT platelet count, AFP alpha-fetoprotein
  3. SLV = 11.5 × body weight (kg) + 334 (Chengdu Formula)